Avidity Partners Management LP 13D and 13G filings for Karyopharm Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:22 pm Sale |
2024-09-30 | 13G | Karyopharm Therapeutics Inc. KPTI |
Avidity Partners Management LP | 316,071 3.700% |
-429,846 (-57.63%) |
Filing |
| 2024-02-14 10:33 am Sale |
2023-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
Avidity Partners Management LP | 745,916 9.500% |
-12,822 (-1.69%) |
Filing |
| 2023-02-14 3:31 pm Purchase |
2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
Avidity Partners Management LP | 758,738 9.900% |
1,950 (+0.26%) |
Filing |
| 2022-12-08 10:22 am Purchase |
2022-12-05 | 13G | Karyopharm Therapeutics Inc. KPTI |
Avidity Partners Management LP | 756,788 9.900% |
756,788 (New Position) |
Filing |